Is oxytocin nasal spray FDA-approved?

No, and it has not been since 1997. FDA did once approve an intranasal oxytocin product — Syntocinon (oxytocin nasal solution) Nasal Spray, NDA 12-285. FDA withdrew approval of that application effective 8 September 1997, by notice published at 62 FR 42575, after the holder notified the agency in writing that the product was no longer marketed and requested withdrawal. There has been no FDA-approved intranasal oxytocin product in the United States since. Every oxytocin nasal spray on the consumer market today is therefore an unapproved product. Read the mechanism of the withdrawal carefully in both directions, because it is easy to spin: it was a commercial withdrawal at the sponsor's request, so it is not a finding that intranasal oxytocin is dangerous — and equally, an approval that was surrendered is the absence of an approval, not an endorsement of the products that filled the gap. Drugs@FDA still lists NDA 012285 with its product in 'Discontinued' marketing status, which is why a database lookup alone will not tell you the approval was withdrawn; the Federal Register notice will.

Does intranasal oxytocin help children with autism?

The largest placebo-controlled trial to report on that question did not find a benefit on its primary outcome. In SOARS-B (NCT01944046), a Phase 2 double-blind trial of 290 children and adolescents with autism spectrum disorder, investigators randomised participants to an intranasal oxytocin spray or to a matched placebo spray containing every other ingredient in the same quantities, and measured change on the Aberrant Behavior Checklist modified social withdrawal subscale over a 24-week double-blind phase. The posted results report a p value of 0.503 for oxytocin versus placebo on that primary outcome, by mixed-models analysis adjusted for baseline, age category and functionality category; a 24-week open-label extension likewise reported no significant difference between the original assignment groups (p = 0.61). This is a genuine human administration trial, not an endogenous-biomarker study: intranasal oxytocin was given to participants, the registration records the intervention type as DRUG, the trial is completed, and results are posted rather than absent. One Phase 2 trial in one population is not the last word on intranasal oxytocin, but it is the best-powered answer currently posted to this question, and it is negative.

Why does the Pitocin label say it is not indicated for elective induction of labor?

Because FDA's stated ground is that the evidence is insufficient, not that the practice is harmful. The FDA-approved Pitocin labeling opens its INDICATIONS AND USAGE section with an 'IMPORTANT NOTICE' defining elective induction as 'the initiation of labor in a pregnant individual who has no medical indications for induction' and stating: 'Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.' FDA's structured product labeling carries that paragraph in the section coded as the label's boxed warning. Two things follow and neither is what the sentence is usually taken to mean. It is a statement about missing data, so it is not a finding that oxytocin causes harm in elective induction. And it is a negative indication, so it does not make elective induction unlawful — prescribing outside a labeled indication is a decision for a licensed clinician, and it is simply a use this label does not support.

Is oxytocin on FDA's 503A bulk drug substances list?

No. Oxytocin appears in none of Categories 1, 2 or 3 of FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026 — verified by fetching that document and searching its full text, which returns zero hits for the word. That absence means something different from BPC-157's absence, and conflating the two is the most common error in this area. BPC-157 was nominated, sat in Category 2, and left the list when the nominators withdrew their nominations. Oxytocin was never in this system at all: a 503A bulks nomination is a route for substances that have no FDA-approved product, and oxytocin has five applications with prescription-status products in Drugs@FDA. Categorical silence here is neither permission nor a safety finding, and it does not answer whether any particular compounded oxytocin preparation is lawful — that question turns on other parts of section 503A that this record does not reach.

What are the labeled risks of oxytocin?

Serious ones, and they are recorded in FDA's own approved labeling rather than inferred. The Pitocin label lists adverse reactions reported in the mother including anaphylactic reaction, subarachnoid hemorrhage, fatal afibrinogenemia, cardiac arrhythmia, hypertensive episodes, postpartum hemorrhage, pelvic hematoma and rupture of the uterus, and states that severe water intoxication with convulsions and coma has occurred and that maternal death due to oxytocin-induced water intoxication has been reported. In the fetus or neonate it lists bradycardia, arrhythmias, low Apgar scores at five minutes, neonatal jaundice, neonatal retinal hemorrhage, neonatal seizures, permanent CNS or brain damage and fetal death. The label's PRECAUTIONS section adds that maternal deaths due to hypertensive episodes, subarachnoid hemorrhage and uterine rupture, and fetal deaths due to various causes, have been reported in association with parenteral oxytocic drugs used for induction or augmentation of labor. Two framing points. These reactions are described for an intravenous product given under continuous professional monitoring — the label's entire WARNINGS section requires exactly that — so they are not a direct read-across to any other route. And the label separately states there are no animal or human studies on the carcinogenicity and mutagenicity of oxytocin, nor any information on its effect on fertility, which is a blank rather than a clean result.

Does the Pitocin label name the clinical trials the approval was based on?

No. The FDA-approved Pitocin labeling has no Clinical Studies section, and its entire REFERENCES list is four Am J Obstet Gynecol papers published between 1982 and 1984 — three by Seitchik and colleagues on oxytocin augmentation of dysfunctional labor, one by Fuchs and colleagues on the initiation of human parturition — plus ACOG Technical Bulletin Number 110 from November 1987. None of the five is identified in the label as a trial supporting the approval, and the label contains no section in which such a trial could be described. Drugs@FDA records the original application as approved on 19 November 1980 under the classification 'Type 5 - New Formulation or New Manufacturer', which is not the pathway on which a molecule's efficacy is established for the first time. That is why this record carries no evidence tier: we could not name and open an adequate, well-controlled efficacy trial for the approved indications, and we do not assign ratings we cannot show our work for. It is not a claim that oxytocin does not work — FDA's approval stands and the label is actively maintained, most recently revised in March 2026.

Oxytocin

Also sold as: Pitocin, Syntocinon, oxytocin injection USP, OT, the love hormone, the bonding hormone

Oxytocin is the active ingredient in FDA-approved drug products, and every approved indication is obstetric. Drugs@FDA lists five oxytocin applications with prescription-status products — Pitocin (NDA 018261), NDA 018243, NDA 018248, ANDA 200219 and ANDA 091676 — and every one of them is an injectable. The FDA-approved Pitocin labeling indicates it for initiation or improvement of uterine contractions to achieve vaginal delivery, for induction of labor in patients with a medical indication, for stimulation or reinforcement of labor, as adjunctive therapy in incomplete or inevitable abortion, and to produce uterine contractions during the third stage of labor and control postpartum bleeding or hemorrhage. There is no approved indication for bonding, trust, intimacy, social anxiety, autism or postpartum depression. That same labeling states that 'Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor', and warns that when given for induction or augmentation it 'should be administered only by the intravenous route and with adequate medical supervision in a hospital'. No FDA-approved intranasal oxytocin product exists: the only one FDA ever approved, Syntocinon nasal spray (NDA 12-285), had its approval withdrawn effective 8 September 1997 at the holder's request after the product was no longer marketed, and the Syntocinon injection (NDA 18-245) was withdrawn the same way effective 18 June 2009. Peptides101 has not assigned an evidence tier to oxytocin, because the Pitocin label carries no Clinical Studies section and names no pivotal efficacy trial, and we do not assign tiers we cannot show our work for.

Which molecule this is. A nonapeptide. The FDA-approved labeling describes Pitocin as 'a sterile, clear, colorless aqueous solution of synthetic oxytocin, for intravenous infusion or intramuscular injection', prepared synthetically 'to avoid possible contamination with vasopressin (ADH) and other small polypeptides with biologic activity'. The disambiguation that matters here is not sequence — it is ROUTE AND PRODUCT. Every oxytocin product FDA currently approves is an injection. Oxytocin sold as a nasal spray, a sublingual troche, an oral drop or a 'research' vial is not one of those products, and the approval, the labeling and the labeled warnings recorded below describe the injections and nothing else. One pharmacology note the label itself flags, because it explains a real risk rather than decorating the entry: oxytocin 'even in its pure form has inherent pressor and antidiuretic properties which may become manifest when large doses are administered', which the label attributes to the fact 'that oxytocin and vasopressin differ in regard to only two of the eight amino acids'. The antidiuretic effect is the mechanism behind the water-intoxication deaths recorded under safety signals.

FDA status

FDA-approved

FDA has approved this as a drug. Approval is always for a specific indication and a specific population — check which one, because it is frequently not the use it is marketed for.

APPROVED, and the word is doing less work than it looks. Drugs@FDA returns nine applications containing oxytocin as an active ingredient. Five carry products in 'Prescription' marketing status: NDA 018261 (PITOCIN, PH Health), NDA 018243 (Hikma), NDA 018248 (Fresenius Kabi USA), ANDA 200219 (Hikma Farmaceutica) and ANDA 091676 (Sagent). Every one of them is an INJECTABLE. Four are discontinued, and two of those four had their approvals affirmatively WITHDRAWN by Federal Register notice — the Syntocinon nasal spray in 1997 and the Syntocinon injection in 2009, both recorded with their own sources under fdaFindings. So the status of this molecule is genuinely split by route: approved as an injection, and no approved product of any kind for the intranasal route where the consumer market lives. A single 'FDA-approved' badge cannot express that, which is why this note exists. QUERY METHOD, recorded because it changes the answer: searching openfda.generic_name returns only 3 of these 9 applications and silently drops both Syntocinon records. The active-ingredient field was used instead. A short count from the openfda block is an artifact of the query, not a fact about the database.

Drugs@FDA — applications containing the active ingredient OXYTOCIN (openFDA API) — FDA, 31 July 2026Checked against the source on 2 August 2026.

Evidence

Not yet verified

We have not finished verifying this against primary sources yet, so we are not going to tell you.

We have not verified this yet.

Not assigned, and the reason is specific rather than a shrug. The usual shortcut for an FDA-approved drug is to read the pivotal trials out of the label — for oxytocin that shortcut is unavailable, because the FDA-approved Pitocin labeling has NO Clinical Studies section and names no pivotal efficacy trial. Its entire REFERENCES list is four Am J Obstet Gynecol papers from 1982-1984 by Seitchik and colleagues plus a 1987 ACOG technical bulletin. Those four were looked up in PubMed on 2026-08-02 and are indexed as Journal Article and Comparative Study — none is indexed as a randomised controlled trial. Drugs@FDA further records the original Pitocin application as approved 1980-11-19 under classification 'Type 5 - New Formulation or New Manufacturer', which is not the route by which a molecule's efficacy is first established. We therefore cannot yet name, open and administration-check an adequate and well-controlled trial establishing efficacy for the approved obstetric indications, and we will not assign a tier we cannot show our work for. READ THIS PRECISELY, BECAUSE IT WILL BE MISREAD IN BOTH DIRECTIONS. This is a statement about the state of OUR verification. It is not a claim that oxytocin does not work: FDA approved these products and continues to approve them, which is a regulatory finding of substantial evidence, and it is recorded and sourced above. Equally, it is not a licence to assume the approval covers anything outside the label. One trial HAS been opened and checked in full, and it runs against the use this compound is actually marketed for: SOARS-B (NCT01944046), a placebo-controlled trial in which intranasal oxytocin was administered to 290 children and adolescents with autism spectrum disorder, reported a p value of 0.503 on its primary social-reciprocity outcome. That trial, its administration check and its result are recorded with their own source in the FAQs below.

We would rather leave this blank than guess. Filling it with something plausible is what the rest of this category does.

What FDA actually approved

Application: NDA 018261 (Pitocin, PH Health); NDA 018243 (Hikma); NDA 018248 (Fresenius Kabi USA); ANDA 200219 (Hikma Farmaceutica); ANDA 091676 (Sagent) — all injectable — Pitocin
Approved indication: IMPORTANT NOTICE — Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor. Antepartum — Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. It is indicated for (1) induction of labor in patients with a medical indication for the initiation of labor, such as Rh problems, maternal diabetes, preeclampsia at or near term, when delivery is in the best interests of mother and fetus or when membranes are prematurely ruptured and delivery is indicated; (2) stimulation or reinforcement of labor, as in selected cases of uterine inertia; (3) as adjunctive therapy in the management of incomplete or inevitable abortion. In the first trimester, curettage is generally considered primary therapy. In second trimester abortion, oxytocin infusion will often be successful in emptying the uterus. Other means of therapy, however, may be required in such cases. Postpartum — Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.

Recorded verbatim, in full, because the gap between this text and the marketed use is the most valuable thing on this record. Read what is here and what is not. EVERY indication is obstetric. Induction of labour where there is a medical indication, augmentation of labour, management of incomplete or inevitable abortion, third-stage uterine contraction, and control of postpartum bleeding. There is no indication for bonding, attachment, trust, intimacy, social anxiety, autism, postpartum depression, breastfeeding or milk letdown. Those are not narrower or broader readings of the text above; they are absent from it. Note also that the label opens the indications section by RULING OUT a use — elective induction — on the express ground that 'the available data are inadequate'. A negative indication stated in the first paragraph of INDICATIONS AND USAGE is unusual, and it is the clearest signal in the document that the evidence base here is narrower than the drug's ubiquity suggests. `discontinued` is false because five applications carry Prescription-status products. Four other applications are discontinued and two of those were affirmatively withdrawn; both are recorded separately below. SCOPE OF THIS FIELD: it is the Pitocin label and it covers NDA 018261. The other four marketed applications carry their own labeling, not read for this pass.

PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021Checked against the source on 2 August 2026.

What FDA found

FDA’s own words. These are the most citable thing on this site, and the least likely to appear anywhere funded by someone selling the compound.

The FDA-approved Pitocin labeling states that elective induction of labor is the initiation of labor in a pregnant individual who has no medical indications for induction, and that since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.
The most-cited sentence in this label and the most-misdescribed. It is not a finding that elective induction is harmful. FDA's stated ground is evidentiary — 'the available data are inadequate to evaluate the benefits-to-risks considerations' — which is a statement about the absence of evidence, and this site does not convert an absence into a finding in either direction. Worth knowing that obstetric practice and this paragraph are not in step: elective induction at term is common, and the labelling has not been revised to bless it. That gap is real, it is between a label and a practice, and adjudicating it is a matter for clinicians and for FDA, not for this record.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.”
Checked against the source on 2 August 2026.
The elective-induction paragraph is carried in the section that FDA's structured product labeling returns as the BOXED WARNING for Pitocin (NDA 018261), SPL version 15, effective 2026-05-06.
Recorded as a separate, separately sourced finding because the claim 'oxytocin carries a boxed warning' is repeated everywhere and is easy to state slightly wrong. What is verifiable is this: the openFDA label endpoint returns the text above in the `boxed_warning` field for all four current SPLs under NDA 018261, which means the SPL codes it as the boxed-warning section. Two precisions the shorthand loses. (1) Its heading in the printed label is 'IMPORTANT NOTICE', not 'WARNING'. (2) Its content is a NEGATIVE INDICATION resting on inadequate data, not a description of a documented harm — unlike, say, semaglutide's thyroid C-cell boxed warning, which describes a finding in rodents. Same structural position in the label, different kind of statement. The genuinely alarming material in this label is elsewhere, in ADVERSE REACTIONS and PRECAUTIONS, and is recorded under safety signals.
PITOCIN (oxytocin injection, USP) — current structured product labeling, NDA 018261 (openFDA API) — FDA, 6 May 2026
“IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.”
Checked against the source on 2 August 2026.
FDA withdrew approval of NDA 12-285, Syntocinon (oxytocin nasal solution) Nasal Spray, effective 8 September 1997. The application holder notified FDA in writing that the product was no longer marketed and requested that approval be withdrawn, waiving the opportunity for a hearing.
THE FINDING THIS RECORD EXISTS TO PUBLISH. FDA did once approve an intranasal oxytocin product. That approval was withdrawn in 1997, and there has been no FDA-approved intranasal oxytocin product in the United States since. Every nasal oxytocin spray on the consumer market today is therefore an unapproved product, whatever else is true about it. Now read the mechanism, because the inversion is available here and sellers run it on sermorelin already. The withdrawal was REQUESTED BY THE HOLDER because the product was no longer marketed. It was not a safety finding and not an efficacy finding, and nothing in this notice says intranasal oxytocin was found dangerous. It equally says nothing good: a commercial withdrawal is the absence of an approval, not an endorsement of what replaced it. Note also what the withdrawn product was and was not. It was a prescription drug product with a label, a strength and a manufacturer. It is not the same thing as an unlabelled spray bought online, and the existence of the old approval is not retrospective cover for the new products.
Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications (62 FR 42575) — FDA, 7 August 1997
“The holders of the applications listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. … NDA 12-285 Syntocinon (oxytocin nasal solution) Nasal Spray … approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective September 8, 1997.”
Checked against the source on 2 August 2026.
FDA withdrew approval of NDA 18-245, Syntocinon (oxytocin) Injection, Novartis Pharmaceuticals Corp., effective 18 June 2009, on the same basis — the holder notified FDA the product was no longer marketed and requested withdrawal.
Recorded so that the phrase 'Syntocinon' resolves to two different products rather than one. The nasal spray (NDA 12-285) went in 1997; the injection (NDA 18-245) went in 2009. A brand name is not a product, and 'Syntocinon' identifies neither on its own. Readers of this library will recognise the citation: 74 FR 23407 is the same Federal Register notice that withdrew sermorelin's GEREF applications, effective the same day.
Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications (74 FR 23407) — FDA, 19 May 2009
“NDA 18-245 Syntocinon (oxytocin) Injection … approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective June 18, 2009.”
Checked against the source on 2 August 2026.
Oxytocin appears in none of Categories 1, 2 or 3 of FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 2026-05-14.
Recorded to close a misreading, not to assert a status — which is why this record carries no compoundingStatus field at all. Verified by fetching the document with a browser user-agent and text-extracting it locally on 2026-08-02: zero hits for 'oxytocin' anywhere in seven pages. This absence means something different from BPC-157's absence. BPC-157 was nominated and left Category 2 when the nominators withdrew. Oxytocin was never in this system: a 503A bulks nomination is a route for substances WITHOUT an approved product, and oxytocin has five marketed applications. Categorical silence here is neither permission nor a safety finding, and it answers no question about whether any particular compounded oxytocin preparation is lawful — that turns on other parts of section 503A which this record does not reach.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.
The FDA-approved Pitocin labeling contains no Clinical Studies section. Its entire REFERENCES list is four Am J Obstet Gynecol papers published 1982-1984 and one 1987 ACOG technical bulletin.
This is why this record's evidence tier is verification-pending, and it is a fact about the label rather than a criticism of the drug. There is no section of this label from which a pivotal trial can be read. The four papers were looked up in PubMed on 2026-08-02. All four are real, all four administered oxytocin to labouring women, and none is indexed as a randomised controlled trial — PubMed's publication types are Journal Article and, for two of them, Comparative Study. A small sourcing error found by opening them, recorded because this site's whole method is opening the citation: the label's second reference is numbered 'II. Multiparous patients'. Volume and pages (145:777-780) are correct, but the paper at that citation is numbered III in the series; part II is 'Uterine activity data', 145:526-529. The roman numeral in the label is wrong. Nothing turns on it — it is reported because a library that only reports the errors it finds in other people's documents is not doing the check.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“REFERENCES Seitchik J, Castillo M: Oxytocin augmentation of dysfunctional labor. I. Clinical data. Am J Obstet Gynecol 1982; 144:899–905. Seitchik J, Castillo M: Oxytocin augmentation of dysfunctional labor. II. Multiparous patients. Am J Obstet Gynecol 1983; 145:777-780. Fuchs A, Goeschen K, Husslein P, et al: Oxytocin and the initiation of human parturition. III. … Am J Obstet Gynecol 1983; 145:497–502. Seitchik J, Amico J, et al: Oxytocin augmentation of dysfunctional labor. IV. Oxytocin pharmacokinetics. Am J Obstet Gynecol 1984; 150:225–228. American College of Obstetricians and Gynecologists: ACOG Technical Bulletin Number 110—November 1987: Induction and augmentation of labor.”
Checked against the source on 2 August 2026.
Drugs@FDA records the original Pitocin application (NDA 018261) as approved 1980-11-19 with submission classification 'Type 5 - New Formulation or New Manufacturer'.
Recorded because it explains the previous finding rather than duplicating it. A Type 5 application is a new formulation or a new manufacturer of an already-established drug — it is not the pathway on which a molecule's efficacy is established for the first time. Oxytocin's clinical use long predates this application and long predates the modern trial apparatus. The honest summary: the approval is real and current, the label has been maintained (most recently revised March 2026), and the evidentiary record that originally supported it is not something this label lets you read. Those three things are all true at once, and any account that drops one of them is selling something.
Drugs@FDA — applications containing the active ingredient OXYTOCIN (openFDA API) — FDA, 31 July 2026Checked against the source on 2 August 2026.

Documented safety signals

The FDA-approved Pitocin labeling restricts route and setting: Pitocin, when given for induction of labor or augmentation of uterine activity, should be administered only by the intravenous route and with adequate medical supervision in a hospital.
The entire WARNINGS section of this label is that one sentence, and it is the sentence furthest from how the consumer market uses this molecule. The approved product is restricted to a route (intravenous), a setting (hospital) and a condition (adequate medical supervision). Read the scope honestly: the sentence is written about induction and augmentation of labour, which is what the label covers. It is not a finding about intranasal oxytocin for social use, because FDA has not made one. What it does establish is that FDA's own risk assessment of oxytocin was made on the assumption of continuous professional monitoring — and the PRECAUTIONS section spells out why, requiring 'continuous observation by trained personnel' and a physician qualified to manage complications 'immediately available'. None of that assumption survives contact with a spray bottle bought online.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“WARNINGS Pitocin, when given for induction of labor or augmentation of uterine activity, should be administered only by the intravenous route and with adequate medical supervision in a hospital.”
Checked against the source on 2 August 2026.
Adverse reactions reported in the mother in the FDA-approved Pitocin labeling include anaphylactic reaction, premature ventricular contractions, postpartum hemorrhage, pelvic hematoma, cardiac arrhythmia, subarachnoid hemorrhage, fatal afibrinogenemia, hypertensive episodes, nausea, rupture of the uterus and vomiting. The labeling states that severe water intoxication with convulsions and coma has occurred, and that maternal death due to oxytocin-induced water intoxication has been reported.
Reproduced because 'it's just a natural hormone' is doing enormous work in this market. The water-intoxication mechanism is the one worth understanding rather than memorising: the label states elsewhere that oxytocin 'has been shown to have an intrinsic antidiuretic effect, acting to increase water reabsorption from the glomerular filtrate', which it attributes to oxytocin and vasopressin differing at only two of eight amino acid positions. That is a property of the molecule, not of the obstetric setting. QUOTE HANDLING: FDA's sentence names an infusion duration alongside the description of the infusion. It is truncated with an ellipsis under this site's no-dosing policy. No finding depends on the elided words — the deaths are the finding.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“The following adverse reactions have been reported in the mother: Anaphylactic reaction … Subarachnoid hemorrhage … Fatal afibrinogenemia … Rupture of the uterus … Severe water intoxication with convulsions and coma has occurred, associated with a slow oxytocin infusion… Maternal death due to oxytocin-induced water intoxication has been reported.”
Checked against the source on 2 August 2026.
Adverse reactions reported in the fetus or neonate in the FDA-approved Pitocin labeling include bradycardia, premature ventricular contractions and other arrhythmias, permanent CNS or brain damage, fetal death, low Apgar scores at five minutes, neonatal jaundice, neonatal retinal hemorrhage and neonatal seizures.
Recorded separately from the maternal list because the label separates them, and because the label attributes them to two distinct causes it names in its own headings: 'Due to induced uterine motility' and 'Due to use of oxytocin in the mother'. The PRECAUTIONS section adds that 'Maternal deaths due to hypertensive episodes, subarachnoid hemorrhage, rupture of the uterus, and fetal deaths due to various causes have been reported associated with the use of parenteral oxytocic drugs for induction of labor or for augmentation in the first and second stages of labor.' These are labeled reactions in a supervised hospital setting, reported to a manufacturer under a regulatory duty. There is no equivalent reporting channel for an unapproved nasal spray, which means the absence of comparable reports about those products is not information.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“The following adverse reactions have been reported in the fetus or neonate: Due to induced uterine motility: … Bradycardia … Permanent CNS or brain damage … Fetal death … Neonatal seizures have been reported with the use of Pitocin.”
Checked against the source on 2 August 2026.
The FDA-approved Pitocin labeling states there are no animal or human studies on the carcinogenicity and mutagenicity of oxytocin, nor any information on its effect on fertility, and that animal reproduction studies have not been conducted with oxytocin.
A blank in FDA's own document, recorded as a blank. This is tolerable for a drug given over hours in a delivery room and evaluated on that basis — the label's own reasoning for the absence of teratogenicity data is that there are 'no known indications for use in the first trimester of pregnancy other than in relation to spontaneous or induced abortion'. It is a materially different blank for a product taken repeatedly over months or years, which is what the bonding and social-anxiety market is. The approved label's silence on long-term exposure is not reassurance about long-term exposure; it is the consequence of a short-exposure indication. Nobody has run those studies because the approved use never required them.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“There are no animal or human studies on the carcinogenicity and mutagenicity of this drug, nor is there any information on its effect on fertility. … Animal reproduction studies have not been conducted with oxytocin.”
Checked against the source on 2 August 2026.

Questions people actually ask

Every answer cites the document behind it. Where the honest answer is “nobody knows”, that is the answer you will get.

Is oxytocin FDA-approved for bonding, trust, or social anxiety?: No. Every indication in the FDA-approved labeling for Pitocin (oxytocin injection, USP, NDA 018261) is obstetric. The label indicates it for the initiation or improvement of uterine contractions in order to achieve vaginal delivery, for induction of labor in patients with a medical indication such as Rh problems, maternal diabetes or preeclampsia at or near term, for stimulation or reinforcement of labor in selected cases of uterine inertia, as adjunctive therapy in the management of incomplete or inevitable abortion, and to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Bonding, attachment, trust, intimacy, social anxiety, autism, postpartum depression and milk letdown appear nowhere in it. Those uses are not narrower or broader readings of the approved indication — they are absent from the document. Note also the route: the approved products are injections given in hospital, so a nasal spray or sublingual troche sold for any of those purposes is not the approved product, and this approval says nothing about it.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“Antepartum: Pitocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. … Postpartum: Pitocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage.”
Checked against the source on 2 August 2026.
Is oxytocin nasal spray FDA-approved?: No, and it has not been since 1997. FDA did once approve an intranasal oxytocin product — Syntocinon (oxytocin nasal solution) Nasal Spray, NDA 12-285. FDA withdrew approval of that application effective 8 September 1997, by notice published at 62 FR 42575, after the holder notified the agency in writing that the product was no longer marketed and requested withdrawal. There has been no FDA-approved intranasal oxytocin product in the United States since. Every oxytocin nasal spray on the consumer market today is therefore an unapproved product. Read the mechanism of the withdrawal carefully in both directions, because it is easy to spin: it was a commercial withdrawal at the sponsor's request, so it is not a finding that intranasal oxytocin is dangerous — and equally, an approval that was surrendered is the absence of an approval, not an endorsement of the products that filled the gap. Drugs@FDA still lists NDA 012285 with its product in 'Discontinued' marketing status, which is why a database lookup alone will not tell you the approval was withdrawn; the Federal Register notice will.
Sterling Drug, Inc., et al.; Withdrawal of Approval of 28 New Drug Applications, 9 Abbreviated Antibiotic Applications, and 46 Abbreviated New Drug Applications (62 FR 42575) — FDA, 7 August 1997
“NDA 12-285 Syntocinon (oxytocin nasal solution) Nasal Spray … approval of the applications listed in the table in this document, and all amendments and supplements thereto, is hereby withdrawn, effective September 8, 1997.”
Checked against the source on 2 August 2026.
Does intranasal oxytocin help children with autism?: The largest placebo-controlled trial to report on that question did not find a benefit on its primary outcome. In SOARS-B (NCT01944046), a Phase 2 double-blind trial of 290 children and adolescents with autism spectrum disorder, investigators randomised participants to an intranasal oxytocin spray or to a matched placebo spray containing every other ingredient in the same quantities, and measured change on the Aberrant Behavior Checklist modified social withdrawal subscale over a 24-week double-blind phase. The posted results report a p value of 0.503 for oxytocin versus placebo on that primary outcome, by mixed-models analysis adjusted for baseline, age category and functionality category; a 24-week open-label extension likewise reported no significant difference between the original assignment groups (p = 0.61). This is a genuine human administration trial, not an endogenous-biomarker study: intranasal oxytocin was given to participants, the registration records the intervention type as DRUG, the trial is completed, and results are posted rather than absent. One Phase 2 trial in one population is not the last word on intranasal oxytocin, but it is the best-powered answer currently posted to this question, and it is negative.
SOARS-B — Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors (NCT01944046) — ClinicalTrials.gov, 5 January 2021
“Change in Aberrant Behavior Checklist-Modified Social Withdrawal Subscale ABC-mSW, a Measure of Social Reciprocity … p-Value 0.503 … Mixed Models Analysis … adjusted for baseline, age category, functionality category”
Checked against the source on 2 August 2026.
Why does the Pitocin label say it is not indicated for elective induction of labor?: Because FDA's stated ground is that the evidence is insufficient, not that the practice is harmful. The FDA-approved Pitocin labeling opens its INDICATIONS AND USAGE section with an 'IMPORTANT NOTICE' defining elective induction as 'the initiation of labor in a pregnant individual who has no medical indications for induction' and stating: 'Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.' FDA's structured product labeling carries that paragraph in the section coded as the label's boxed warning. Two things follow and neither is what the sentence is usually taken to mean. It is a statement about missing data, so it is not a finding that oxytocin causes harm in elective induction. And it is a negative indication, so it does not make elective induction unlawful — prescribing outside a labeled indication is a decision for a licensed clinician, and it is simply a use this label does not support.
PITOCIN (oxytocin injection, USP) — current structured product labeling, NDA 018261 (openFDA API) — FDA, 6 May 2026
“IMPORTANT NOTICE Elective induction of labor is defined as the initiation of labor in a pregnant individual who has no medical indications for induction. Since the available data are inadequate to evaluate the benefits-to-risks considerations, Pitocin is not indicated for elective induction of labor.”
Checked against the source on 2 August 2026.
Is oxytocin on FDA's 503A bulk drug substances list?: No. Oxytocin appears in none of Categories 1, 2 or 3 of FDA's list of bulk drug substances nominated for use in compounding under section 503A, updated 14 May 2026 — verified by fetching that document and searching its full text, which returns zero hits for the word. That absence means something different from BPC-157's absence, and conflating the two is the most common error in this area. BPC-157 was nominated, sat in Category 2, and left the list when the nominators withdrew their nominations. Oxytocin was never in this system at all: a 503A bulks nomination is a route for substances that have no FDA-approved product, and oxytocin has five applications with prescription-status products in Drugs@FDA. Categorical silence here is neither permission nor a safety finding, and it does not answer whether any particular compounded oxytocin preparation is lawful — that question turns on other parts of section 503A that this record does not reach.
Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act — FDA, 14 May 2026Checked against the source on 2 August 2026.
What are the labeled risks of oxytocin?: Serious ones, and they are recorded in FDA's own approved labeling rather than inferred. The Pitocin label lists adverse reactions reported in the mother including anaphylactic reaction, subarachnoid hemorrhage, fatal afibrinogenemia, cardiac arrhythmia, hypertensive episodes, postpartum hemorrhage, pelvic hematoma and rupture of the uterus, and states that severe water intoxication with convulsions and coma has occurred and that maternal death due to oxytocin-induced water intoxication has been reported. In the fetus or neonate it lists bradycardia, arrhythmias, low Apgar scores at five minutes, neonatal jaundice, neonatal retinal hemorrhage, neonatal seizures, permanent CNS or brain damage and fetal death. The label's PRECAUTIONS section adds that maternal deaths due to hypertensive episodes, subarachnoid hemorrhage and uterine rupture, and fetal deaths due to various causes, have been reported in association with parenteral oxytocic drugs used for induction or augmentation of labor. Two framing points. These reactions are described for an intravenous product given under continuous professional monitoring — the label's entire WARNINGS section requires exactly that — so they are not a direct read-across to any other route. And the label separately states there are no animal or human studies on the carcinogenicity and mutagenicity of oxytocin, nor any information on its effect on fertility, which is a blank rather than a clean result.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“The following adverse reactions have been reported in the mother: Anaphylactic reaction … Subarachnoid hemorrhage … Fatal afibrinogenemia … Rupture of the uterus … Maternal death due to oxytocin-induced water intoxication has been reported.”
Checked against the source on 2 August 2026.
Does the Pitocin label name the clinical trials the approval was based on?: No. The FDA-approved Pitocin labeling has no Clinical Studies section, and its entire REFERENCES list is four Am J Obstet Gynecol papers published between 1982 and 1984 — three by Seitchik and colleagues on oxytocin augmentation of dysfunctional labor, one by Fuchs and colleagues on the initiation of human parturition — plus ACOG Technical Bulletin Number 110 from November 1987. None of the five is identified in the label as a trial supporting the approval, and the label contains no section in which such a trial could be described. Drugs@FDA records the original application as approved on 19 November 1980 under the classification 'Type 5 - New Formulation or New Manufacturer', which is not the pathway on which a molecule's efficacy is established for the first time. That is why this record carries no evidence tier: we could not name and open an adequate, well-controlled efficacy trial for the approved indications, and we do not assign ratings we cannot show our work for. It is not a claim that oxytocin does not work — FDA's approval stands and the label is actively maintained, most recently revised in March 2026.
PITOCIN (oxytocin injection, USP) — FDA-approved labeling, NDA 018261, supplement 041 — FDA, 11 May 2021
“REFERENCES Seitchik J, Castillo M: Oxytocin augmentation of dysfunctional labor. I. Clinical data. Am J Obstet Gynecol 1982; 144:899–905. … American College of Obstetricians and Gynecologists: ACOG Technical Bulletin Number 110—November 1987: Induction and augmentation of labor.”
Checked against the source on 2 August 2026.